Jovčevska I - Search Results

1

Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review.

Zottel A, Jovčevska I, Šamec N, Komel R. Zottel A, et al. Among authors: jovcevska i. Crit Rev Oncol Hematol. 2021 Apr;160:103283. doi: 10.1016/j.critrevonc.2021.103283. Epub 2021 Mar 2. Crit Rev Oncol Hematol. 2021. PMID: 33667657 Free article. Review.

2

Glioma and glioblastoma - how much do we (not) know?

Jovčevska I, Kočevar N, Komel R. Jovčevska I, et al. Mol Clin Oncol. 2013 Nov;1(6):935-941. doi: 10.3892/mco.2013.172. Epub 2013 Aug 26. Mol Clin Oncol. 2013. PMID: 24649273 Free PMC article. Review.

3

TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers.

Jovčevska I, Zupanec N, Kočevar N, Cesselli D, Podergajs N, Stokin CL, Myers MP, Muyldermans S, Ghassabeh GH, Motaln H, Ruaro ME, Bourkoula E, Turnšek TL, Komel R. Jovčevska I, et al. PLoS One. 2014 Nov 24;9(11):e113688. doi: 10.1371/journal.pone.0113688. eCollection 2014. PLoS One. 2014. PMID: 25419715 Free PMC article.

4

Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates.

Jovčevska I, Zupanec N, Urlep Ž, Vranič A, Matos B, Stokin CL, Muyldermans S, Myers MP, Buzdin AA, Petrov I, Komel R. Jovčevska I, et al. Oncotarget. 2017 Jul 4;8(27):44141-44158. doi: 10.18632/oncotarget.17390. Oncotarget. 2017. PMID: 28498803 Free PMC article.

5

Sequencing the next generation of glioblastomas.

Jovčevska I. Jovčevska I. Crit Rev Clin Lab Sci. 2018 Jun;55(4):264-282. doi: 10.1080/10408363.2018.1462759. Epub 2018 Apr 18. Crit Rev Clin Lab Sci. 2018. PMID: 29668342 Review.

6

Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting.

Samec N, Jovcevska I, Stojan J, Zottel A, Liovic M, Myers MP, Muyldermans S, Šribar J, Križaj I, Komel R. Samec N, et al. Among authors: jovcevska i. Oncotarget. 2018 Apr 3;9(25):17282-17299. doi: 10.18632/oncotarget.24629. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707108 Free PMC article.

7

Meta-Analysis and Experimental Validation Identified FREM2 and SPRY1 as New Glioblastoma Marker Candidates.

Vidak M, Jovcevska I, Samec N, Zottel A, Liovic M, Rozman D, Dzeroski S, Juvan P, Komel R. Vidak M, et al. Among authors: jovcevska i. Int J Mol Sci. 2018 May 4;19(5):1369. doi: 10.3390/ijms19051369. Int J Mol Sci. 2018. PMID: 29734672 Free PMC article.

8

Nanotechnology Meets Oncology: Nanomaterials in Brain Cancer Research, Diagnosis and Therapy.

Zottel A, Videtič Paska A, Jovčevska I. Zottel A, et al. Among authors: jovcevska i. Materials (Basel). 2019 May 15;12(10):1588. doi: 10.3390/ma12101588. Materials (Basel). 2019. PMID: 31096609 Free PMC article. Review.

9

High FREM2 Gene and Protein Expression Are Associated with Favorable Prognosis of IDH-WT Glioblastomas.

Jovčevska I, Zottel A, Šamec N, Mlakar J, Sorokin M, Nikitin D, Buzdin AA, Komel R. Jovčevska I, et al. Cancers (Basel). 2019 Jul 27;11(8):1060. doi: 10.3390/cancers11081060. Cancers (Basel). 2019. PMID: 31357584 Free PMC article.

10

Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma.

Šamec N, Zottel A, Videtič Paska A, Jovčevska I. Šamec N, et al. Among authors: jovcevska i. Molecules. 2020 Jan 23;25(3):490. doi: 10.3390/molecules25030490. Molecules. 2020. PMID: 31979318 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page